DK1611111T3 - Fremgangsmåde til resolvering af 2,4-diamino-3,6-dihydro-1,3,5-triaziner der er egnede til behandling af lidelser som er forbundet med insulinresistenssyndrom - Google Patents

Fremgangsmåde til resolvering af 2,4-diamino-3,6-dihydro-1,3,5-triaziner der er egnede til behandling af lidelser som er forbundet med insulinresistenssyndrom

Info

Publication number
DK1611111T3
DK1611111T3 DK04725892T DK04725892T DK1611111T3 DK 1611111 T3 DK1611111 T3 DK 1611111T3 DK 04725892 T DK04725892 T DK 04725892T DK 04725892 T DK04725892 T DK 04725892T DK 1611111 T3 DK1611111 T3 DK 1611111T3
Authority
DK
Denmark
Prior art keywords
diamino
resolving
dihydro
treatment
insulin resistance
Prior art date
Application number
DK04725892T
Other languages
Danish (da)
English (en)
Inventor
Gerard Moinet
Daniel Cravo
Thierry Passemar
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1611111T3 publication Critical patent/DK1611111T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK04725892T 2003-04-10 2004-04-06 Fremgangsmåde til resolvering af 2,4-diamino-3,6-dihydro-1,3,5-triaziner der er egnede til behandling af lidelser som er forbundet med insulinresistenssyndrom DK1611111T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0304486A FR2853650B1 (fr) 2003-04-10 2003-04-10 Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
PCT/EP2004/002476 WO2004089917A2 (en) 2003-04-10 2004-04-06 Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disorders associated with insulin resistance syndrome

Publications (1)

Publication Number Publication Date
DK1611111T3 true DK1611111T3 (da) 2009-05-18

Family

ID=33041769

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04725892T DK1611111T3 (da) 2003-04-10 2004-04-06 Fremgangsmåde til resolvering af 2,4-diamino-3,6-dihydro-1,3,5-triaziner der er egnede til behandling af lidelser som er forbundet med insulinresistenssyndrom

Country Status (23)

Country Link
US (1) US7501511B2 (de)
EP (1) EP1611111B1 (de)
JP (1) JP4836778B2 (de)
KR (1) KR101107665B1 (de)
CN (1) CN100383130C (de)
AR (1) AR044511A1 (de)
AT (1) ATE425151T1 (de)
AU (1) AU2004228125B2 (de)
BR (1) BRPI0409258B8 (de)
CA (1) CA2521879C (de)
CY (1) CY1109609T1 (de)
DE (1) DE602004019897D1 (de)
DK (1) DK1611111T3 (de)
ES (1) ES2321718T3 (de)
FR (1) FR2853650B1 (de)
MX (1) MXPA05010764A (de)
PL (1) PL214955B1 (de)
PT (1) PT1611111E (de)
RU (1) RU2344131C2 (de)
SI (1) SI1611111T1 (de)
TW (1) TWI344464B (de)
WO (1) WO2004089917A2 (de)
ZA (1) ZA200509071B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
CN101468986B (zh) * 2007-12-26 2010-12-29 香港南北兄弟国际投资有限公司 一种二氢嘧啶消旋化合物的拆分方法
DE102008007314A1 (de) * 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
CA2725011A1 (en) * 2008-05-23 2009-11-26 Poxel Sas Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
HRP20160318T1 (hr) 2008-07-29 2016-05-06 Poxel Postupak izolacije enantiomernih komponenti iz smjesa enantiomera pomoću kristalizacije kontrolirane veličinom čestica
DE102009014898A1 (de) * 2009-03-25 2010-09-30 Merck Patent Gmbh Prozess zur Enantiomerentrennung von 3,6-Dihydro-1,3,5-triazinderivaten
ES2436633T3 (es) * 2009-03-26 2014-01-03 Poxel Procedimiento para la separación de enantiómeros de dihidro-1,3,5-triazinas racémicas por cristalización preferencial
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
ES2577930T3 (es) * 2010-06-09 2016-07-19 Poxel Derivados de triazina para retrasar el inicio de la diabetes tipo 1
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
RS54397B1 (sr) * 2010-12-01 2016-04-28 Poxel Odvajanje enantiomera triazin derivata pomoću vinske kiseline
US11617754B2 (en) 2017-10-02 2023-04-04 Poxel Sa Methods of treating heart failure with preserved ejection fraction
MX2020013210A (es) 2018-06-06 2021-02-26 Metavant Sciences Gmbh Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica.
EP3806828A1 (de) 2018-06-14 2021-04-21 Poxel Filmbeschichtete tablette mit einem triazinderivat zur verwendung in der behandlung von diabetes
CN114763339A (zh) * 2021-01-13 2022-07-19 江苏恒瑞医药股份有限公司 三嗪衍生物的制备方法
CN115087643B (zh) * 2021-01-15 2023-10-27 中国医药研究开发中心有限公司 稠和杂环类化合物及其制备方法和医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894027A (en) * 1973-07-31 1975-07-08 Merck & Co Inc Resolution of racemic reticuline and racemization of its enantiomers
JPS5414986A (en) * 1977-07-01 1979-02-03 Taiho Pharmaceutical Co Ltd Production of dihydrooss triazine derivative
JPH0436279A (ja) * 1990-06-01 1992-02-06 Kyowa Hakko Kogyo Co Ltd 光学活性なベンゾオキセピン誘導体の製造法
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
WO1997011074A1 (en) * 1995-09-22 1997-03-27 Fujisawa Pharmaceutical Co., Ltd. Novel processes for producing pyridoindole derivatives
MX9805870A (de) * 1996-01-22 1999-01-31
JPH11193270A (ja) * 1997-12-26 1999-07-21 Koei Chem Co Ltd 光学活性１−メチル−３−ピペリジンメタノールの製造方法
JP4138928B2 (ja) * 1998-02-20 2008-08-27 山川薬品工業株式会社 Ｄ−アロイソロイシンの製造方法および製造の中間体
FR2775974B1 (fr) * 1998-03-16 2000-08-18 Rhodia Chimie Sa Procede de separation de diastereoisomeres d'une diphosphine et preparation de diphosphines optiquement actives
EP1091944A1 (de) * 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-one, 1,3-benzoxazepin-2-one als inhibitor der reversen transkriptase
JP2001199972A (ja) * 2000-01-20 2001-07-24 Eisai Co Ltd 光学活性ピペラジン誘導体の製造法
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
JP2002193933A (ja) * 2000-06-14 2002-07-10 Toray Ind Inc 光学活性ピペリジン誘導体またはその酸塩の製造方法
DE10042064A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10125131A1 (de) * 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram

Also Published As

Publication number Publication date
AR044511A1 (es) 2005-09-14
JP2006522753A (ja) 2006-10-05
WO2004089917A3 (en) 2004-12-23
RU2344131C2 (ru) 2009-01-20
SI1611111T1 (sl) 2009-08-31
BRPI0409258B1 (pt) 2018-05-15
KR20050120791A (ko) 2005-12-23
ES2321718T3 (es) 2009-06-10
CN100383130C (zh) 2008-04-23
PL214955B1 (pl) 2013-10-31
US7501511B2 (en) 2009-03-10
PL377833A1 (pl) 2006-02-20
CN1771233A (zh) 2006-05-10
PT1611111E (pt) 2009-06-18
DE602004019897D1 (de) 2009-04-23
ATE425151T1 (de) 2009-03-15
BRPI0409258A (pt) 2006-03-28
WO2004089917A2 (en) 2004-10-21
AU2004228125A1 (en) 2004-10-21
US20060223803A1 (en) 2006-10-05
TW200504037A (en) 2005-02-01
TWI344464B (en) 2011-07-01
BRPI0409258B8 (pt) 2021-05-25
CA2521879A1 (en) 2004-10-21
RU2005134685A (ru) 2006-06-10
CA2521879C (en) 2013-01-08
EP1611111A2 (de) 2006-01-04
FR2853650B1 (fr) 2006-07-07
MXPA05010764A (es) 2005-12-12
EP1611111B1 (de) 2009-03-11
ZA200509071B (en) 2007-04-25
KR101107665B1 (ko) 2012-01-20
JP4836778B2 (ja) 2011-12-14
CY1109609T1 (el) 2014-08-13
AU2004228125B2 (en) 2010-07-15
HK1088002A1 (en) 2006-10-27
FR2853650A1 (fr) 2004-10-15

Similar Documents

Publication Publication Date Title
PT1611111E (pt) Processo para resolução de aminas que são uteis no tratamento de patologias associadas à síndrome de resistência à insulina
DK1633726T3 (da) Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
DK3351246T3 (da) Rapamycinderivat til behandling af en solid tumor, som er associeret med dereguleret angionese
DK1656372T3 (da) 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
CL2004000526A1 (es) Compuestos derivados de dibenzofurano, carbazoles, inhibidores de fosfodiesterasa tipo 4; procedimiento de preparacion; y su uso en el tratamiento de trastornos y condiciones inflamatorias, del sistema nervioso central y diabetes insulino resistente.
DK1265615T3 (da) Ny kombination af ikkesederende antihistaminika med substanser, der påvirker leukotrien-virkningen, til behandling af rhinitis/conjunctivtis
DK1632234T3 (da) (S,S)-reboxetin til behandling af kronisk træthedssyndrom
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
ECSP067095A (es) Compuestos y metodos para el tratamiento de dislipidemia
DK2545939T3 (da) Tetrahydrobiopterin til behandling af tilstande associeret med forhøjede phenylalaninniveauer
DK1678185T3 (da) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazolforbindelser til behandling af tuberkulose
DK2314632T3 (da) Oligosaccharidforbindelser, der er afledt af heparin
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
DK1656346T3 (da) 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme
DK2177224T3 (da) Forbindelse til forebyggelse og behandling af lidelser, som involverer modulation af RyR-receptorerne
DK2263723T3 (da) Injektor af pentype med dosisindstillingsmuffe
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
DK1610796T3 (da) Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade
DK1868600T3 (da) Spirocyklisk cyclohexanderivat til behandling af stofafhængighed
DK1421075T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister til behandling af HIV
DK1765355T3 (da) Benzoxazin til behandling af luftvejslidelser
DK1776136T3 (da) Behandling af tilstande, der involverer demyelinisering